LUNGevity Foundation released its first Lung Cancer Scorecard that grades individual states on policies that support access to optimal care for lung cancer patients. These grades were assigned based upon five factors: coverage for lung cancer screening, coverage for comprehensive biomarker testing, Medicaid expansion, lung cancer incidence, and lung cancer survival.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
